Evaluate the Efficacy and Safety of Different Doses of Edaravone Dexborneol Concentrated Solution for Injection Combined With Conventional Medical Therapy in the Treatment of Patients With Cerebral Hemorrhage

NCT05953103 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
80
Enrollment
OTHER
Sponsor class

Stopped This study was terminated after completing the first dose level of Sanbenxin 37.5 mg due to the decision made by the sponsor that a new clinical development program for the new form of sublingual tablets would replace the existing plan.

Conditions

Interventions

Sponsor

Simcere Pharmaceutical Co., Ltd